TWi Pharmaceuticals appoints Tina Guilder as president and chief executive

5 March 2015

Taiwanese pharma company Twi Pharmaceuticals has appointed Tina Guilder as president and chief executive officer.

The current president, Calvin Chen, will become Ms Guilder’s special adviser and remain as president of Twi Biotechnology. The board has also decided to appoint Eva Ho as the chief financial officer of the company.

Prior to joining Twi, Ms Guilder was the vice president of business development and alliance management at Teva Pharmaceuticals USA (NYSE: TEVA), and has more than 18 years of experience in the pharma and healthcare industry, with emphasis on finance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK